 |
|
aclarubicin
An oligosaccharide anthracycline antineoplastic antibiotic isolated from the bacterium Streptomyces galilaeus. Aclarubicin intercalates into DNA and interacts with topoisomerases I and II, thereby inhibiting DNA replication and repair and RNA and protein synthesis. Aclarubicin is antagonistic to other agents that inhibit topoisomerase II, such as etoposide, teniposide and amsacrine. This agent is less cardiotoxic than doxorubicin and daunorubicin. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)
| Synonyms: | | aclacinomycin
Aclacinomycin A
Aclacinomycin A hydrochloride
aclacinomycin-A
Aclarubicin Hydrochloride
Antibiotic MA144-A1 | | | | Foreign brand names: | | Aclacin
Aclacinomycine
Aclacinon
Aclaplastin
Jaclacin | | | | Abbreviations: | | ACM
ACM-A | | | | Code name: | | MA144-A1 | | | | Chemical structure names: | | - [1R-(1alpha,2beta,4beta)]-2-ethyl-1,2,3,4,6,11-hexahydro-2,5,7-trihydroxy-6,11-dioxo-4-[[2,3,6-trideoxy-4-O-[2,6-dideoxy-4-O-[(2R-trans)-tetrahydeo-6-methyl-5-oxo-2H-pyran-2-yl]-alpha-L-lyxo-hexopyranosyl]-3-(dimethylamino-alpha-L-lyxo-hexopyranosyl)oxy]-
- [1R-(1alpha,2beta,4beta)]-2-ethyl-1,2,3,4,6,11-hexahydro-2,5,7-trihydroxy-6,11-dioxo-4-[[2,3,6-trideoxy-4-O-[2,6-dideoxy-4-O-[(2R-trans)-tetrahydro-6-methyl-5-oxo-2H-pyran-2-yl]-alpha-L-lyxo-hexopyranosyl]-3-(dimethylamino-alpha-L-lyxo-hexopyranosyl)oxy]-1-naphthacenecarboxylic acid methyl ester
- 1-naphthacenecarboxylic acid, 2-ethyl-1,2,3,4,6,11-hexahydro-2,5, 7-trihydroxy-6,11-dioxo-4-[[2,3,6-trideoxy-4-O-[2,6-dideoxy-4-O-((2R-trans)-tetrahydro-6-methyl-5-oxo-2H-pyran-2-yl) -.alpha.-L-lyxo-hexopyranosyl]-3-(dimethylamino)-.alpha.-L-lyxo-hexopyranosyl]oxy]-, methyl ester,(1R-(1.alpha.,2.beta.,4.beta.))-(9CI)
| | |
|
|
